Loading...
•
Sep 30, 2020
United Therapeutics Q3 2020 Earnings Report
United Therapeutics' financial performance reflected strong growth in Orenitram® and Tyvaso® net revenue, offset by a decline in overall revenues due to decreased Remodulin® and Adcirca® sales. The company is preparing for several key product launches in 2021.
Key Takeaways
United Therapeutics reported a decrease in total revenues by 5% year-over-year, but experienced growth in Orenitram® and Tyvaso® net revenues. Net income increased by 29% and the company is preparing for multiple product launches in 2021.
Orenitram® net revenue increased by 20% year-over-year.
Tyvaso® net revenue increased by 17% year-over-year.
Remodulin® sequential quarterly net revenue grew by 5%.
INCREASE sNDA is under FDA review with an action date in April 2021; Remunity™ launch preparations are ongoing.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
United Therapeutics anticipates launching Tyvaso for a new indication, along with Remunity Pump, Trevyent system, and Implantable System for Remodulin in the near-term.
Positive Outlook
- Potential INCREASE product label expansion for Tyvaso
- Launch of the Remunity Pump for Remodulin
- Launch of the Implantable System for Remodulin
- Resumption of enrollment in several clinical studies
- Focus on pediatric use of Unituxin
Challenges Ahead
- Delays in commercial sales of Remunity Pump due to pandemic-related supply chain issues
- Complete response letter from FDA regarding Trevyent NDA
- Delay in ISR launch until 2021 due to Medtronic satisfying PMA approval conditions
- Potential delays in completion and data readouts for ongoing and planned studies due to the pandemic
- Discontinuation of development of LNG01
Revenue & Expenses
Visualization of income flow from segment revenue to net income